Provided by Tiger Fintech (Singapore) Pte. Ltd.

NRX Pharmaceuticals Inc.

2.35
+0.280013.53%
Post-market: 2.31-0.0400-1.70%19:59 EDT
Volume:260.95K
Turnover:597.82K
Market Cap:39.67M
PE:-1.11
High:2.41
Open:2.09
Low:2.08
Close:2.07
Loading ...

Company Profile

Company Name:
NRX Pharmaceuticals Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
- -
Office Location:
1201 Orange Street,Suite 600,Wilmington,Delaware,United States
Zip Code:
19801
Fax:
- -
Introduction:
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Directors

Name
Position
Stephen H. Willard
Chief Executive Officer, Director
Jonathan C. Javitt
Chief Scientist Officer, Director
Aaron Gorovitz
Director
Chaim Hurvitz
Director
Patrick J. Flynn
Director
Sharon A. Glied
Director

Shareholders

Name
Position
Stephen H. Willard
Chief Executive Officer, Director
Richard Narido
Interim Chief Financial Officer
Jonathan C. Javitt
Chief Scientist Officer, Director
Riccardo Panicucci
CMC and Technical Operations Advisor